| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 10/15/2026 | ±1.5% | +4.6% | under-priced |
| 07/21/2026 | ±2.3% | -0.3% | over-priced |
| 04/16/2026 | ±2.6% | +4.4% | under-priced |
| 02/09/2026 | ±2.6% | -7.5% | under-priced |
| 10/16/2025 | ±1.7% | -8.5% | under-priced |
| 07/17/2025 | ±1.7% | -0.4% | over-priced |
| 04/17/2025 | ±2.9% | -4.9% | under-priced |
| 02/10/2025 | ±1.6% | +0.3% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q3 FY2026 | $1.69 | $6.9B | $808M |
| Q2 FY2026 | $2.63 | $7.4B | $1.3B |
| Q1 FY2026 | $2.36 | $7.6B | $1.1B |
| Q4 FY2025 | — | $6.6B | $821M |
MRSH (MRSH) reports in 79 days, with the next report estimated for 01/14/2027. Across the last 8 reports, options priced an average ±2.1% earnings move while the stock actually moved 3.9% on average — the market has been roughly fair on MRSH's earnings risk. Fundamentals into the print: EPS up 11.9% year-over-year, revenue up 8.1%. QuantLogix's live 5-factor engine currently reads MRSH as a buy at 69/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →